Kochenderfer, James N.

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 2,898

Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.

Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 1,730

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 1,595

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood

CAR-T cell therapy researchT-cell and B-cell Immunology

Cited by 1,337

Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels

Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S. L., Yang, J. C., Sherry, R. M., et al. (2017) · Journal of Clinical Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 569

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy

Yamamoto, T. N., Lee, P.-H., Vodnala, S. K., Gurusamy, D., Kishton, R. J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L., et al. (2019) · Journal of Clinical Investigation

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 156

Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics

Panch, S. R., Srivastava, S. K., Elavia, N., McManus, A., Liu, S., Jin, P., Highfill, S. L., Li, X., Dagur, P., Kochenderfer, J. N., et al. (2019) · Molecular Therapy

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 107

Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days

Mikkilineni, L., Yates, B., Steinberg, S. M., Shahani, S. A., Molina, J. C., Palmore, T., Lee, D. W., Kaplan, R. N., Mackall, C. L., Fry, T. J., et al. (2021) · Blood Advances

CAR-T cell therapy researchNeutropenia and Cancer Infections

Cited by 75

Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics

Elavia, N., Panch, S. R., McManus, A., Bikkani, T., Szymanski, J., Highfill, S. L., Jin, P., Brudno, J., Kochenderfer, J., & Stroncek, D. F. (2019) · Transfusion

CAR-T cell therapy researchT-cell and B-cell Immunology

Cited by 43

Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma

Kochenderfer, J. N., Somerville, R., Lu, L., Iwamoto, A., Yang, J. C., Klebanoff, C., Kammula, U., Sherry, R. M., Victoria, S., Yuan, C., et al. (2014) · Blood

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 33

Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain

Mikkilineni, L., Natrakul, D. A., Lam, N., Manasanch, E. E., Mann, J., Weissler, K. A., Wong, N., Brudno, J. N., Goff, S. L., Yang, J. C., et al. (2024) · Molecular Therapy

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 16

Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity

Mikkilineni, L., Manasanch, E. E., Natrakul, D., Brudno, J. N., Mann, J., Goff, S. L., Yang, J. C., Lam, N., Maric, I., Stetler-Stevenson, M., et al. (2021) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 9